Roche in $44 billion bid for remainder of Genentech
This article was originally published in Scrip
Swiss pharma Rochehas offered to buy the 44% of its US partner Genentechthat it does not already own for $43.7 billion as it seeks to better leverage the pipeline and R&D of the biotech bellwether. Roche acquired a majority interest in Genentech in 1990.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.